Shares of Intrexon Corp (NYSE:XON) fell 6.8% during trading on Tuesday . The stock traded as low as $15.77 and last traded at $15.90. 1,373,065 shares changed hands during trading, a decline of 31% from the average session volume of 1,984,631 shares. The stock had previously closed at $17.06.
Several brokerages recently commented on XON. Bank of America cut their price objective on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, March 2nd. Northland Securities reissued a “buy” rating and set a $17.00 price objective on shares of Intrexon in a research report on Friday, March 2nd. JPMorgan Chase & Co. reissued a “neutral” rating and set a $18.00 price objective (down from $22.00) on shares of Intrexon in a research report on Monday, March 5th. Zacks Investment Research raised shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Finally, ValuEngine cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $34.67.
The company has a current ratio of 1.92, a quick ratio of 1.67 and a debt-to-equity ratio of 0.01. The company has a market cap of $2,207.03, a P/E ratio of -16.22 and a beta of 1.30.
Intrexon (NYSE:XON) last posted its earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.08. The business had revenue of $77.03 million for the quarter, compared to analysts’ expectations of $48.16 million. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The business’s revenue for the quarter was up 67.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.37) EPS. research analysts expect that Intrexon Corp will post -0.92 earnings per share for the current year.
In related news, CEO Randal J. Kirk bought 1,000,000 shares of the stock in a transaction on Friday, January 19th. The shares were acquired at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 56.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Third Security LLC lifted its stake in Intrexon by 2.5% during the 4th quarter. Third Security LLC now owns 57,928,289 shares of the biotechnology company’s stock valued at $667,334,000 after acquiring an additional 1,423,236 shares during the period. Greenwich Wealth Management LLC bought a new position in shares of Intrexon in the 4th quarter worth approximately $576,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intrexon by 493.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 11,854 shares during the period. Peregrine Capital Management LLC lifted its stake in shares of Intrexon by 10.7% in the 4th quarter. Peregrine Capital Management LLC now owns 645,596 shares of the biotechnology company’s stock worth $7,437,000 after purchasing an additional 62,268 shares during the period. Finally, Dynamic Technology Lab Private Ltd lifted its stake in shares of Intrexon by 127.0% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 24,640 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 13,783 shares during the period. Institutional investors and hedge funds own 75.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Intrexon (XON) Stock Price Down 6.8%” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thestockobserver.com/2018/03/20/intrexon-xon-stock-price-down-6-8.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.